In response to the letter to the editor “IgA nephropathy and hematuria after getting vaccine for SARS-CoV-2” in response to our letter titled “Hematuria in patients with IgA nephropathy after vaccine for SARS-CoV-2” we would like to clarify some considerations in order to appropriately interpret the reason for said letter.

Although it is true that the sample size of our letter is small (3 patients), at the time of carrying out the literature review (August/2021), all published series were less than 5 patients. This is supported by the bibliographic reviews that accompany our letter (see bibliography).

None of the patients presented urinary infections or had a history of kidney stones, which could suggest a possible bias, since they were asymptomatic. They also did not present respiratory symptoms that could suggest covert SARS-CoV2 infection.

Undoubtedly, and despite the communication in our letter, the benefit of administering the vaccine in this group of patients is above the side effects of hematuria, which is non-specific in these cases, due to the high mortality in this respiratory infection in our patients.